A functional Immunology Platform to Accelerate Drug Development
immunXnano is a pioneering deep biotech spin-off project from the German Center for Neurodegenerative Diseases (DZNE) dedicated to revolutionizing immunosafety profiling for the next generation of safe and effective therapeutics.
immunXnano has developed a cutting-edge technology that accelerates the development of safe and effective drugs, nanomedicines, and vaccines by providing unprecedented insights into immune system interactions on a functional level leveraging primary human cells.
Its proprietary assay and analysis platform captures high-dimensional phenotypic data from individual blood immune cells, revealing subtle cellular responses to (nano-)drug stimuli and donor heterogeneity. The scalable approach allows for precise functional profiling of immune activation, cytokine signaling and cytotoxicity — key factors in predicting therapeutic efficacy and safety.
Pharmaceutical and biotech companies benefit from reduced development risks, faster regulatory compliance and safer nanomedicine.
immunXnano technology can be applied in all stages of drug development
Generate actionable insights on immune activation, cytokine signaling, and toxicity using scalable, high dimensional phenotyping of primary human cells
Powered by Real human Immune Data
Proprietary Database of >50.000 compounds
Referenced against >500 qualified donors
Fine tuning of innate immune activation and cytotoxicity to accelerate hit-to-lead screening of vaccines
- hit-to-lead screening identified Silvacx’s lead candidate in <4 weeks
- candidate shows functional innate immune activation and effective TNFa induction ex vivo and in vivo (murine model) without causing inflammatory toxicity
- lead candidate completing pre-IND
Let us revolutionize immunX safety together!
De-risk & test your candidates with us!
A deep biotech Spinoff project by DZNE
Supported through:
